Sanofi SA (NYSE:SNY) – Investment analysts at Jefferies Financial Group issued their Q2 2019 earnings estimates for shares of Sanofi in a note issued to investors on Wednesday, July 10th. Jefferies Financial Group analyst P. Welford forecasts that the company will post earnings per share of $0.64 for the quarter. Jefferies Financial Group also issued estimates for Sanofi’s Q3 2019 earnings at $1.13 EPS, Q4 2019 earnings at $0.70 EPS, FY2019 earnings at $3.29 EPS, FY2020 earnings at $3.62 EPS and FY2021 earnings at $3.94 EPS.
Sanofi (NYSE:SNY) last released its quarterly earnings data on Friday, April 26th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The firm had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.34 billion. During the same quarter in the prior year, the company posted $1.28 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis.
Shares of SNY stock opened at $41.28 on Friday. Sanofi has a 12 month low of $40.19 and a 12 month high of $45.62. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. The company’s 50 day moving average is $42.80. The firm has a market capitalization of $103.05 billion, a P/E ratio of 13.19, a PEG ratio of 2.41 and a beta of 0.67.
Several large investors have recently made changes to their positions in SNY. Bank of New York Mellon Corp increased its stake in shares of Sanofi by 79.7% in the fourth quarter. Bank of New York Mellon Corp now owns 280,659 shares of the company’s stock valued at $12,184,000 after buying an additional 124,476 shares in the last quarter. Bessemer Group Inc. increased its position in Sanofi by 11.8% in the fourth quarter. Bessemer Group Inc. now owns 2,409 shares of the company’s stock worth $104,000 after purchasing an additional 255 shares during the period. Brown Advisory Inc. increased its position in Sanofi by 1.2% in the fourth quarter. Brown Advisory Inc. now owns 81,497 shares of the company’s stock worth $3,538,000 after purchasing an additional 955 shares during the period. Geode Capital Management LLC increased its position in Sanofi by 10.8% in the fourth quarter. Geode Capital Management LLC now owns 56,590 shares of the company’s stock worth $2,456,000 after purchasing an additional 5,525 shares during the period. Finally, BOKF NA increased its position in Sanofi by 30.4% in the fourth quarter. BOKF NA now owns 8,288 shares of the company’s stock worth $360,000 after purchasing an additional 1,932 shares during the period. Institutional investors own 7.04% of the company’s stock.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
See Also: Why do companies issue stock splits?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.